Association of clinical severity with FANCB variant type in Fanconi anemia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
30 04 2020
Historique:
received: 10 09 2019
accepted: 12 02 2020
pubmed: 28 2 2020
medline: 22 12 2020
entrez: 28 2 2020
Statut: ppublish

Résumé

Fanconi anemia (FA) is the most common genetic cause of bone marrow failure and is caused by inherited pathogenic variants in any of 22 genes. Of these, only FANCB is X-linked. We describe a cohort of 19 children with FANCB variants, from 16 families of the International Fanconi Anemia Registry. Those with FANCB deletion or truncation demonstrate earlier-than-average onset of bone marrow failure and more severe congenital abnormalities compared with a large series of FA individuals in published reports. This reflects the indispensable role of FANCB protein in the enzymatic activation of FANCD2 monoubiquitination, an essential step in the repair of DNA interstrand crosslinks. For FANCB missense variants, more variable severity is associated with the extent of residual FANCD2 monoubiquitination activity. We used transcript analysis, genetic complementation, and biochemical reconstitution of FANCD2 monoubiquitination to determine the pathogenicity of each variant. Aberrant splicing and transcript destabilization were associated with 2 missense variants. Individuals carrying missense variants with drastically reduced FANCD2 monoubiquitination in biochemical and/or cell-based assays tended to show earlier onset of hematologic disease and shorter survival. Conversely, variants with near-normal FANCD2 monoubiquitination were associated with more favorable outcome. Our study reveals a genotype-phenotype correlation within the FA-B complementation group of FA, where severity is associated with level of residual FANCD2 monoubiquitination.

Identifiants

pubmed: 32106311
pii: S0006-4971(20)62066-3
doi: 10.1182/blood.2019003249
pmc: PMC7193183
doi:

Substances chimiques

FANCB protein, human 0
Fanconi Anemia Complementation Group Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1588-1602

Subventions

Organisme : Howard Hughes Medical Institute
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

PLoS One. 2014 Jan 09;9(1):e85313
pubmed: 24416387
Mol Cell. 2017 Jan 19;65(2):247-259
pubmed: 27986371
Mol Syndromol. 2013 Feb;4(1-2):87-93
pubmed: 23653579
Nat Genet. 2004 Nov;36(11):1219-24
pubmed: 15502827
Mol Genet Genomic Med. 2018 Jan;6(1):77-91
pubmed: 29193904
Blood. 2006 Sep 15;108(6):2072-80
pubmed: 16720839
Pediatr Res. 2020 Feb;87(3):541-549
pubmed: 31499513
EMBO J. 2007 Apr 18;26(8):2104-14
pubmed: 17396147
Cell. 2007 Apr 20;129(2):289-301
pubmed: 17412408
Hum Mol Genet. 2015 Sep 15;24(18):5234-49
pubmed: 26123487
Bioinformatics. 2012 May 1;28(9):1216-22
pubmed: 22408192
J Med Genet. 2006 Sep;43(9):750-4
pubmed: 16679491
Bioinformatics. 2014 Mar 1;30(5):660-7
pubmed: 24130308
Mol Cell. 2014 Jun 5;54(5):858-69
pubmed: 24905007
Cell Rep. 2015 Jul 7;12(1):35-41
pubmed: 26119737
Am J Med Genet A. 2016 Jun;170(6):1520-4
pubmed: 27028275
Hum Mutat. 2018 Feb;39(2):237-254
pubmed: 29098742
Blood. 2013 May 30;121(22):e138-48
pubmed: 23613520
Proteomics. 2015 Sep;15(18):3163-8
pubmed: 25656970
Am J Med Genet. 1997 Jan 10;68(1):58-61
pubmed: 8986277
Cell. 2015 Jan 15;160(1-2):354-354.e1
pubmed: 25594185
Nat Protoc. 2016 Dec;11(12):2357-2375
pubmed: 27809318
Congenit Anom (Kyoto). 2018 Sep;58(5):171-172
pubmed: 29232005
Nature. 2013 Jan 17;493(7432):356-63
pubmed: 23325218
Clin Dysmorphol. 2016 Apr;25(2):73-6
pubmed: 26683739
Blood. 2003 Feb 15;101(4):1249-56
pubmed: 12393516
Hum Mutat. 2014 Nov;35(11):1342-53
pubmed: 25168418
Nature. 2019 Nov;575(7781):234-237
pubmed: 31666700
Haematologica. 2014 Jun;99(6):1022-31
pubmed: 24584348
Blood. 2000 Dec 15;96(13):4064-70
pubmed: 11110674
Cell Rep. 2017 Jan 17;18(3):611-623
pubmed: 27986592
PLoS Genet. 2018 Dec 12;14(12):e1007821
pubmed: 30540754
Haematologica. 2019 Oct;104(10):1962-1973
pubmed: 30792206
Exp Hematol. 2017 Jun;50:27-32
pubmed: 28315701
Annu Rev Cancer Biol. 2019 Mar;3:457-478
pubmed: 30882047
Am J Med Genet A. 2011 Oct;155A(10):2370-80
pubmed: 21910217
Am J Med Genet A. 2011 Dec;155A(12):3071-4
pubmed: 22052692
Annu Rev Biophys. 2014;43:257-78
pubmed: 24773018

Auteurs

Moonjung Jung (M)

Laboratory of Genome Maintenance, The Rockefeller University, New York, NY.

Ramanagouda Ramanagoudr-Bhojappa (R)

Cancer Genomics Unit, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.

Sylvie van Twest (S)

Genome Stability Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia.

Rasim Ozgur Rosti (RO)

Laboratory of Genome Maintenance, The Rockefeller University, New York, NY.

Vincent Murphy (V)

Genome Stability Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia.

Winnie Tan (W)

Genome Stability Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia.

Frank X Donovan (FX)

Cancer Genomics Unit, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.

Francis P Lach (FP)

Laboratory of Genome Maintenance, The Rockefeller University, New York, NY.

Danielle C Kimble (DC)

Cancer Genomics Unit, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.

Caroline S Jiang (CS)

Department of Biostatistics, The Rockefeller University Hospital, The Rockefeller University, New York, NY.

Roger Vaughan (R)

Department of Biostatistics, The Rockefeller University Hospital, The Rockefeller University, New York, NY.

Parinda A Mehta (PA)

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH.

Filomena Pierri (F)

Hematology Unit, IRCSS G. Gaslini, Genoa, Italy; and.

Carlo Dufour (C)

Hematology Unit, IRCSS G. Gaslini, Genoa, Italy; and.

Arleen D Auerbach (AD)

Human Genetics and Hematology Program, The Rockefeller University, New York, NY.

Andrew J Deans (AJ)

Genome Stability Unit, St Vincent's Institute of Medical Research, Melbourne, VIC, Australia.

Agata Smogorzewska (A)

Laboratory of Genome Maintenance, The Rockefeller University, New York, NY.

Settara C Chandrasekharappa (SC)

Cancer Genomics Unit, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH